Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company centered on nitric oxide (NO) technologies, and its news flow reflects both commercial execution and clinical development. Company announcements frequently highlight progress with the LungFit PH system, a cylinder-free NO generator and delivery device approved for treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Investors can follow updates on U.S. hospital adoption, international distribution agreements, regulatory milestones, and quality certifications related to this platform.
News items also cover Beyond Air’s broader LungFit pipeline, including clinical trials evaluating higher-concentration NO for severe lung infections such as viral community-acquired pneumonia and nontuberculous mycobacteria. These stories often discuss regulatory submissions, design patents for next-generation devices, and participation in medical and industry conferences.
On the biopharmaceutical side, Beyond Air and its affiliates generate news about oncology and neurology programs. Beyond Cancer, Ltd. reports early-stage clinical data and preclinical work using ultra-high concentration NO for solid tumors, while NeuroNOS communications describe small-molecule nNOS inhibitors, preclinical findings in Autism Spectrum Disorder and brain cancers, and U.S. FDA Orphan Drug Designations for glioblastoma and Phelan-McDermid Syndrome. Transactions such as the agreement for XTL Biopharmaceuticals to acquire a majority stake in NeuroNOS are also covered.
Capital markets and corporate governance updates are another recurring theme, including private placements, warrant exercises, promissory notes, equity purchase agreements, reverse stock splits, and leadership changes. For investors and analysts tracking XAIR, this news page provides a centralized view of commercial rollouts, clinical milestones, financing activity, and strategic partnerships that shape the company’s nitric oxide-focused portfolio.
Beyond Air (NASDAQ: XAIR) entered a private placement agreement to sell 3,930,818 shares of common stock (or pre-funded warrants) and warrants to purchase up to 3,930,818 shares at a combined purchase price of $1.272 per share/associated warrant, for expected gross proceeds of approximately $5.0 million before fees.
The issued warrants will have an exercise price of $1.147, be exercisable immediately, and expire five years from issuance. Closing is expected on or about January 16, 2026, subject to customary conditions. Rodman & Renshaw is the exclusive placement agent; Roth Capital Partners and D. Boral Capital are financial advisors. Net proceeds will be used for working capital and general corporate purposes.
XTL Biopharmaceuticals (NASDAQ:XTLB) agreed on Jan. 13, 2026 to acquire 85% of NeuroNOS from Beyond Air (NASDAQ:XAIR) to build a disease‑modifying autism and neuro‑oncology platform. Transaction consideration includes 19.9% of XTL share capital to Beyond Air, $1.0M cash, and up to $32.5M in milestone payments (development and commercial). NeuroNOS holds FDA Orphan Drug designations for Phelan‑McDermid Syndrome and glioblastoma. Leadership includes founder Prof. Haitham Amal and two Nobel laureates. The release cites autism prevalence of 1 in 31 U.S. children and notes a $50M NIH allocation for autism research.
Beyond Air (NASDAQ: XAIR) appointed Dan Moorhead as Chief Financial Officer, effective January 5, 2026. Duke Dewrell will resume his prior role as Controller on that date.
Mr. Moorhead brings >20 years of finance leadership, including serving as CFO of Zynex from June 2017 to August 2025. The company granted an inducement option exercisable for 70,000 shares, effective January 5, 2026, with a 10-year term and four-year vesting (25% after one year, then annual thirds). The exercise price equals the last reported Nasdaq sale price on December 31, 2025. The award was approved by the independent compensation committee and is subject to the company's equity incentive plan.
Beyond Air (NASDAQ: XAIR) announced new international distribution agreements for LungFit PH adding Germany, Brazil, Austria, the Netherlands and Sri Lanka and expanding its network to 39 countries.
The agreements cover a combined population of more than three billion people. Beyond Air said some markets will require regulatory approvals that may take time, while others are expected to begin benefiting from LungFit PH in calendar 2026. LungFit PH generates nitric oxide from ambient air, providing a tankless alternative to high‑pressure cylinders intended to streamline hospital operations, improve efficiency and reduce environmental impact.
Beyond Air (NASDAQ: XAIR) announced that Chief Financial Officer Doug Larson resigned to pursue another opportunity and will remain CFO through December 5, 2025. Controller Duke Drewell will assume CFO responsibilities on an interim basis while the company has launched a search for a permanent successor. Mr. Larson will continue in an advisory role through calendar year-end 2025. The company credited Larson with helping the business transition to commercial operations, including the launch of LungFit PH and majority-owned subsidiaries Beyond Cancer and NeuroNOS, and said recent financing agreements strengthened the balance sheet. The departure was stated not to result from any disagreements over financial reporting or policies.
Beyond Air (NASDAQ: XAIR) reported fiscal Q2 2026 results for the quarter ended September 30, 2025 with revenue +128% YoY to $1.8M and an updated fiscal 2026 revenue guidance of $8–$10M. The company closed a financing providing a $12.0M promissory note plus an equity line up to $20M, yielding a proforma cash balance of $22.9M and runway into calendar 2027. Net loss was $7.9M (–$1.25 per share), net cash burn was $4.7M for the quarter, and reported cash and marketable securities were $10.7M with long-term debt of $10.1M. Commercially, LungFit PH expanded to 35 countries, MDSAP certification was achieved, and a PMA supplement for second-generation LungFit PH was submitted in June 2025. Bob Goodman named interim Chief Commercial Officer.
Beyond Air (NASDAQ: XAIR) entered financing agreements with Streeterville Capital providing up to $32 million in potential proceeds: a $12 million promissory note and a $20 million equity line of credit (ELOC). Pro forma cash, cash equivalents, restricted cash and marketable securities totaled $22.9 million as of September 30, 2025, which includes the $12 million note. The promissory note bears 15% annual interest, matures in 24 months with no payments for the first 12 months, and places $6 million in a restricted account. The ELOC allows sale of up to $20 million of common stock over 24 months and requires an S-1 resale registration. Management says the financing extends runway into calendar 2027 and supports LungFit PH commercial expansion and a planned second-generation launch before end of 2026.
Beyond Air (NASDAQ: XAIR) will release second fiscal quarter 2026 financial results for the period ended September 30, 2025 on Monday, November 10, 2025. The company's management will host a conference call and webcast the same day at 4:30 PM Eastern Time to discuss results.
Dial-in details: Domestic 1-877-407-0784, International 1-201-689-8560, Conference ID 13756730. A live webcast will be available in the Events section of the company's website, and an online replay will be posted about one hour after the call.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference. The event will take place on October 9, 2025, in New York, NY.
The company's Chief Financial Officer, Douglas Larson, will be available for one-on-one meetings with investors during the conference. Interested investors can schedule meetings through their Roth Capital Partners representatives.
Beyond Air (NASDAQ: XAIR) has secured approximately $3.25 million in gross proceeds through the exercise of existing warrants. The agreement involves the immediate exercise of warrants to purchase 1,439,126 shares of common stock at a reduced price of $2.21 per share.
As part of the transaction, the company will issue new unregistered warrants to purchase up to 719,561 shares of common stock at $0.0625 per warrant. These new warrants will have an exercise price of $2.21 per share, with immediate exercisability and a five-year term. The proceeds will support Beyond Air's clinical and pre-clinical programs, operating expenses, and working capital.
FAQ
What is the current stock price of Beyond Air (XAIR)?
What is the market cap of Beyond Air (XAIR)?
